Management of Hypercalcemia with Elevated Intact PTH

Initial Diagnostic Differentiation

• The American Journal of Kidney Diseases recommends checking serum phosphorus levels, as elevated phosphorus suggests CKD-related secondary hyperparathyroidism, while low-normal phosphorus suggests primary hyperparathyroidism 1, 2

Management for CKD Patients on Dialysis (Secondary Hyperparathyroidism)

• The National Kidney Foundation recommends targeting serum phosphorus between 3.5-5.5 mg/dL through dietary restriction and phosphate binders, and avoiding calcium-based phosphate binders when hypercalcemia is present 1, 4, 5
• The American Journal of Kidney Diseases suggests not initiating active vitamin D sterols if serum calcium exceeds 9.5 mg/dL or phosphorus exceeds 4.6 mg/dL, and targeting PTH levels of 150-300 pg/mL for dialysis patients 2, 4
• The American Journal of Kidney Diseases recommends using dialysate calcium concentration of 2.5 mEq/L as standard, and considering lowering dialysate calcium to 1.5-2.0 mEq/L temporarily for severe hypercalcemia 2, 5

Management for Patients WITHOUT CKD (Primary Hyperparathyroidism)

• The American College of Physicians recommends initiating aggressive IV crystalloid hydration with normal saline for total calcium ≥12 mg/dL or symptomatic patients, and adding loop diuretics only after adequate volume repletion 3

Critical Pitfalls to Avoid

• The National Kidney Foundation warns against starting vitamin D therapy in CKD patients with uncontrolled hyperphosphatemia, as this dramatically increases vascular calcification risk 4
• The American Journal of Kidney Diseases advises against targeting normal PTH levels in dialysis patients, as PTH <100 pg/mL causes adynamic bone disease 2, 4